Analysts see synergies for both Torrent and Dr Reddy s with Cipla, driven by rationalisation of costs, but also warn that the merger could significantly raise debt levels for the pharma companies.
Though Cipla will be too big to swallow for any Indian pharmaceutical player, either a combination with a private equity company or a plain private equity buyout is possible. The two options have different ramifications for investors.